יחס שווי פעילות לרווח לפני ריבית, מסים ופחת Vivos Therapeutics Inc (VVOS)

Assembly capacities for dental equipment are operating seamlessly while adhering to strict quality standards, although slow market penetration and insurance reimbursement challenges are hindering expansion. This chart of the share price, featuring the 0.00 indicator, confirms the potential of Vivos Therapeutics (VVOS), as certified apnea treatment methods generate a steady profit stream through the recurring sale of software and consumables.

The EV/EBITDA ratio compares the total enterprise value, including debt, with operating profit before depreciation and amortization. By analyzing changes in the EV to EBITDA ratio, an investor assesses the efficiency of capital return, which is critical for Vivos Therapeutics (VVOS) as it implements costly eco-friendly polymers and energy-efficient technologies in the production of apnea treatment devices.